LifeMap Solutions Adds Chief Technology Officer to Leadership Team

Additional Experts from Partner Icahn Institute at Mount Sinai Form Science Team

ALAMEDA, Calif. – Oct 01, 2014 – BioTime, Inc. (NYSE MKT:BTX) and its subsidiary LifeMap Solutions, Inc., a medical technology company, today announced significant additions to the LifeMap Solutions management team. LifeMap Solutions is partnering with the Icahn Institute at Mount Sinai to create innovative mobile health (mHealth) products and services backed by big data. Today the company announced the appointment of Rafhael Cedeno as Chief Technology Officer and Head of Product, as well as the addition of Joel Dudley, PhD, Rong Chen, PhD, and Elissa Levin from the Icahn Institute as members of the LifeMap Solutions science team.

A veteran in big data and consumer technology applications, Rafhael Cedeno comes to LifeMap Solutions with significant experience at Internet and software companies, including his previous role as Vice President of Game Development for Viacom, where he oversaw the development of top-charting iOS and Android apps on the Apple App Store and Google Play, respectively, and provided technical and product direction for other projects at Viacom. Earlier in his career, Mr. Cedeno worked at such influential Internet companies as Netscape and Kontiki. As Chief Technology Officer and Head of Product, Mr. Cedeno will be responsible for overseeing all aspects of product development, including the integration of Mount Sinai’s expertise and data into LifeMap Solutions’ products.

“Adding Rafhael Cedeno to our team is a major win for us,” said LifeMap Solutions CEO Corey Bridges. “He brings to LifeMap Solutions his experience architecting and managing the development of complex technology platforms, coupled with the bold innovation he applies to product design. His history of success in the mobile space meshes perfectly with our needs.”

“This is an exciting time to work in health technology. We are living in an era characterized by an unprecedented ability to analyze enormous quantities of data from sources that weren’t easily accessible previously,” said Mr. Cedeno. “As we work alongside our partners at Mount Sinai, we are uniquely poised to make an impact in the industry.”

In addition, LifeMap Solutions today announced the names of the new members of the company’s science team from their partner, the Icahn Institute at Mount Sinai:

  • Joel Dudley, PhD, Director of Biomedical Informatics
  • Elissa Levin, MS, CGC, Head of Genomics and Integrative Health Innovations
  • Rong Chen, PhD, Director of Clinical Genome Informatics

Eric Schadt, PhD, founding director of the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai, was previously announced as the leading science advisor to LifeMap Solutions. The science team will coordinate with Mr. Cedeno to share knowledge and expertise to build mHealth products and services.

About LifeMap Solutions, Inc.

LifeMap Solutions develops innovative digital health solutions by integrating health and wellness information with care team guidance into a secure mHealth platform to deliver digital health solutions that empower patients to make better choices to achieve optimal health outcomes. LifeMap Solutions is a subsidiary of BioTime, Inc., and is headquartered in San Jose, California. For more information, please visit www.lifemap-solutions.com.

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world’s premier collection of pluripotent stem cell assets. The foundation of our core therapeutic technology platform is pluripotent stem cells that are capable of becoming any of the cell types in the human body. Pluripotent stem cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent stem cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.